Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) has received approval from the National Medical Products Administration for the clinical trial of its dual-target ADC drug RC288, aimed at treating locally advanced unresectable or metastatic malignant solid tumors in Phase I/IIa trials [1] Group 1: Drug Development - RC288 is a dual-specific ADC that targets both PSMA and B7H3, developed using next-generation conjugation and toxin technology [1] - PSMA (Prostate-Specific Membrane Antigen) is a type II transmembrane glycoprotein that supports tumor growth and angiogenesis [1] - B7H3 is an immune checkpoint molecule that, when overexpressed in tumors, promotes immune evasion and tumor progression [1] Group 2: Market Potential - Both PSMA and B7H3 are highly promising therapeutic targets, expressed in various malignant tumor tissues and newly formed tumor blood vessels, and are involved in tumor proliferation, invasion, and drug resistance signaling pathways [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the transfer of the marketing authorization of artificial bile acid metronidazole capsules [1] Group 1 - The product in question is referred to as "artificial bile acid metronidazole capsules" [1] - The approval allows for the transfer of the supplementary application for the marketing authorization holder [1] - The application complies with the relevant requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1]

Group 1 - The core announcement is that Shenzhen Expressway Company (00548.HK) and Shenzhen International (00152.HK) jointly announced the subscription of a structured deposit product with a principal amount of RMB 1.2 billion, effective from April 1, 2026 [1]

Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) has received approval from the National Medical Products Administration for its clinical trial of the dual-antibody ADC drug RC288, aimed at treating locally advanced unresectable or metastatic malignant solid tumors in I/IIa phases [1]. Group 1 - The company announced the receipt of the clinical trial approval notice on April 1 [1]. - The drug RC288 is a self-developed dual-antibody ADC targeting specific cancer types [1]. - The approval marks a significant step in the company's research and development efforts in oncology [1].

Core Viewpoint - The appreciation of the Renminbi has positively impacted related sectors, with a notable increase in stock prices on April 1, 2023, particularly led by China Eastern Airlines [1] Group 1: Market Performance - On April 1, the Shanghai Composite Index closed at 3948.55, up by 1.46% [1] - The Shenzhen Component Index closed at 13706.52, up by 1.7% [1] - The Renminbi appreciation beneficiary sector saw an increase of 2.63% compared to the previous trading day [1] Group 2: Capital Flow - The main capital inflow into the Renminbi appreciation beneficiary sector amounted to a net inflow of 458 million yuan [1] - Retail investors experienced a net outflow of 1.48 billion yuan, while speculative funds saw a net outflow of 309 million yuan [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the transfer of the marketing authorization of artificial bile acid metronidazole capsules, indicating compliance with post-marketing change management requirements [1] Group 1: Company Developments - The company submitted a supplementary application for the change of marketing authorization holder in March 2026, which has now been approved [1] - The approval allows the company to transfer the marketing authorization for the product, which is indicated for acute pericoronitis, local alveolar abscess, pulpitis, and apical periodontitis [1] Group 2: Market Insights - The sales revenue of artificial bile acid metronidazole capsules in Chinese public medical institutions is projected to be approximately RMB 579 million in 2024 [1]

Core Viewpoint - Rongchang Biopharma has received approval from the National Medical Products Administration for its self-developed dual-target ADC drug RC288, which is intended for the treatment of locally advanced unresectable or metastatic malignant solid tumors in a Phase I/IIa clinical trial [1] Group 1: Drug Development - RC288 is a bispecific ADC that targets both PSMA and B7H3, developed using next-generation conjugation and toxin technology [1] - PSMA and B7H3 are highly promising therapeutic targets, expressed in various malignant tumor tissues and tumor neovascularization, and are involved in tumor proliferation, invasion, and drug resistance signaling pathways [1]

Core Viewpoint - Haier Smart Home Co., Ltd. has announced the progress of its A-share repurchase plan, having repurchased a total of 15.35 million shares, accounting for 0.16% of its total share capital, with a total payment of approximately 334 million yuan [1][5]. Repurchase Plan Key Elements - The repurchase plan was first disclosed on March 27, 2026, proposed by the board of directors [2][6]. - The implementation period of the repurchase plan is from March 26, 2026, to March 25, 2027 [2][6]. - The expected repurchase amount ranges from 3 billion yuan to 6 billion yuan [2][6]. - The purpose of the repurchase is for employee stock ownership plans or equity incentives [2][6]. - The cumulative number of shares repurchased is 15,350,000 shares [2][6]. - The cumulative number of repurchased shares accounts for 0.16% of the total share capital [2][6]. - The total amount paid for the repurchase is 334,007,465.88 yuan [2][6]. - The actual repurchase price range is between 21.43 yuan/share and 22.40 yuan/share [2][6]. Repurchase Progress Details - As of the end of March 2026, the company has completed the repurchase operations, having repurchased 15.35 million shares [3][7]. - The highest purchase price was 22.40 yuan/share, while the lowest was 21.43 yuan/share [3][7]. - The total payment made for the repurchase is approximately 334 million yuan [3][7]. - The repurchase actions comply with relevant laws and regulations as well as the company's repurchase plan requirements [3][7]. Future Arrangements - The company will strictly follow the regulations of the "Listed Company Share Repurchase Rules" and the "Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange No. 7 - Share Repurchase" during the repurchase period [4][8]. - The company will implement the repurchase based on market conditions and will fulfill its information disclosure obligations in a timely manner [4][8].

Core Viewpoint - CICC maintains profit forecasts for China Duty Free Group (01880) at RMB 5.483 billion and RMB 6.31 billion for the next two years, while lowering the target price for the company's H-shares and A-shares to RMB 95 and HKD 95 respectively, maintaining an "outperform industry" rating for both [1] Group 1 - China Duty Free Group reported a 4.92% year-on-year decline in revenue for 2025, totaling RMB 53.694 billion, and a 15.96% decrease in net profit attributable to shareholders, amounting to RMB 3.586 billion [1] - The company believes that the performance in the last quarter of the previous year met market expectations [1] Group 2 - Looking ahead to 2026, the firm is optimistic about growth in duty-free sales driven by outbound travelers, island residents, digital products, and organic growth, suggesting continued attention to the rebound from a low year-on-year base [1]

Group 1 - The core viewpoint of the article is that China International Capital Corporation (CICC) maintains its profit forecasts for China Duty Free Group (01880) at 5.483 billion RMB for this year and 6.31 billion RMB for next year, while adjusting the target price for the company's H-shares and A-shares to 95 RMB and 95 HKD respectively due to a decline in industry valuation [1] Group 2 - China Duty Free Group reported a 4.92% year-on-year decrease in revenue to 53.694 billion RMB and a 15.96% year-on-year decrease in net profit attributable to shareholders to 3.586 billion RMB, indicating that the performance in the last quarter of the previous year met market expectations [1] Group 3 - Looking ahead to 2026, the company is optimistic about growth in duty-free sales driven by outbound travelers, island residents, digital products, and organic growth, suggesting that investors should pay attention to the rebound from a low year-on-year base [1]